Gastroenterology

The guidelines include advocating for more preventative care and changing how the disease is diagnosed.

Dupilumab is currently the only treatment for eosinophilic esophagitis approved by the US Food and Drug Administration.

Nearly half of patients treated with vonoprazan 10 mg and 20 mg achieved more 24-hour heartburn free days compared to participants treated by placebo.

Gut microbiota diversity was lower in below average responders, while 39.5% of participants had a serological response below the geometric mean.

There have been more than 12,900 studies on the involvement of dysbiosis in the gensisinfectious diseases in the last 15 years.

The World Health Organization has set a goal of eradication for HCV by 2030.

The FDA requested additional data showing the levels of a nitrosam impurity was below the set threshold throughout the life of vonoprazan.

Ulcerative colitis was considered an independent risk factor, while Crohn’s disease and unclassified inflammatory bowel disease were not.

Previous trials using acupuncture in patients with irritable bowel syndrome have suffered from problems of high placebo response rates.

A group of investigators, researchers and policymakers discuss the issues, innovations and aspirations that may define 2023 advances.

Experts in gastroenterology review the use of IL-23 inhibitors such as guselkumab and risankizumab-rzaa for the management of Crohn’s disease.

Dr Bincy P. Abraham examines age considerations and comorbidities when choosing a therapy for elderly patients with Crohn’s disease.

In part A of the trial, 60% of patients treated with dupilumab weekly met the primary endpoint of histologic remission, compared to 5% of the placebo group.

There was no differences observed in total weight loss at both 6 and 18 months in the fecal microbiota transplantation and placebo groups.

Anita Afzali, MD, MPH, MHCM, FACG, AGAF, explores clinical implications of newer therapies for Crohn’s disease in the real-world setting.

Jennifer Seminerio, MD, discusses long-term outcomes and clinical remission rates for patients on an IL/23 inhibitor for Crohn’s disease.

The results show significant LSM relative reductions compared to pooled placebo in aspartate aminotransferase for pegozafermin 3 mg once weekly, 27 mg once weekly, and 36 mg once every 2 weeks.

Dr Miguel Regueiro comments on the safety and efficacy of approved IL-23 inhibitors and IL-12/23 inhibitors for the treatment of Crohn’s disease.

Jennifer Seminerio, MD, and Bincy P. Abraham, MD, MS, AGAF, FACG, share their perspective on the use of IL-12/23 inhibitors in clinical practice for the management of Crohn’s disease.

In 2021, the USPSTF changed guidance on colorectal cancer screenings, reducing the recommended age of a colonoscopy from 50 to 45 years.

Drs Bincy P. Abraham, Miguel Regueiro, David P. Hudesman, Anita Afzali, and Jennifer Seminerio provide insight on approaching the optimal therapy for patients with Crohn’s disease in the frontline and second-line settings.

Drs Miguel Regueiro, Jennifer Seminerio, Anita Afzali, and David Hudesman review currently available biologic therapies for moderate-to-severe Crohn’s disease and the evolution of the disease treatment landscape.

Prometheus Biosciences is expected to begin phase 3 trials for the treatment in 2023.

The male gender was positively associated with a higher risk of serious infection at month 12 and penetrating disease behavior was positively associated with 12-month treatment persistence.

The product is administered as a single dose and is manufactured using the stool of qualified donors.

Dr Bincy P. Abraham leads a discussion on factors to consider when selecting a therapy for the management of Crohn’s disease.

Experts in gastroenterology review goals of therapy for the management of Crohn’s disease, utilizing a treat-to-target approach for treatment, and the importance of shared decision-making.

Dr Anita Afzali and Dr Bincy P. Abraham review the diagnostic workup for Crohn’s disease and challenges in diagnosing the disease.

Bincy P. Abraham, MD, MS, AGAF, FACG, and Jennifer Seminerio, MD, provide insight on the pathophysiology of Crohn’s Disease (CD), associated risk factors, and diagnosis of disease.

The treatment is a broad-spectrum serine protease inhibitor that acts to neutralize digestive enzymes, can possibly reduce abdominal adhesions and accelerate the return of bowel function following gastrointestinal surgery.